Cite
HARVARD Citation
Ota, T. et al. (n.d.). 1478PEfficacy of second-line nivolumab after early time to progression on first-line cytotoxic chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). Annals of oncology. p. . [Online].